Navigation Links
Major Firms Eyeing CBMS Development of New Glaucoma Treatment
Date:7/7/2009

NEW YORK, MONTREAL and SAN DIEGO, CA, July 7 /PRNewswire-FirstCall/ - Canadian Bio Med Systems Inc., a subsidiary of ICBS Ltd., (OTCPK: ICBT), and Ocular Therapeutics Inc. of San Diego California, announced that Ocular Therapeutics has signed non-disclosure agreements with two of the largest pharmaceutical firms in the world. These unnamed companies are interested in a new treatment approach in the largest of the ophthalmic markets.

High Interest in a New Approach to Glaucoma Treatment

One of the reasons these large entities are so interested in this project is because of a recent article in the "Review of Ophthalmology" supports the development of a new class of glaucoma drugs now being tested by Canadian Bio Med Systems, Inc. (CBMS). The article was identified incorrectly as being from the "Survey of Ophthalmology" in an earlier release. The article entitled "Glaucoma Drugs: The Search for New Options" quotes David Epstein, MD, Chairman of Ophthalmology at Duke University School of Medicine in Durham North Carolina. Dr. Epstein points out that the approach of improving aqueous outflow in the eye is "the most logical approach to treating glaucoma"

Glaucoma is caused by an increase of intraocular pressure within the eye. The new compound being developed by CBMS in conjunction with Ocular Therapeutics, Inc. of California, specifically targets a portion of the eye, Schlemm's Canal, which is critical in achieving aqueous outflow and lowering intraocular pressure. This novel approach to treatment may require application of the drug every three months, or even less often, rather that twice per day. It could revolutionize the treatment for glaucoma.

Dr. Epstein points out the commercial aspects of such a potential drug that improves aqueous outflow by saying that when such a drug is developed "you will see every major pharmaceutical company jump on the bandwagon and want to have an outflow drug". Further he says, "Then in retrospect, every one will say 'Why didn't we work on this drug sooner'".

CBMS is completing the studies required to enter into human clinical trials in centers both in the United States and Canada.

The drug for the treatment of glaucoma is being developed by Daniel Stamer, PhD and Ronald Heimark, PhD at the University of Arizona. Glaucoma is a prevalent eye disease is one of the leading causes of blindness in the world. Patient compliance is a serious problem in glaucoma because of the frequency which conventional medication is required. The new drug being developed may change the paradigm of glaucoma therapy.

NB. This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a result of any number of factors, including the risk factors contained in the Company's disclosure documents.


'/>"/>
SOURCE ICBS Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Urine Drug Test to Detect for 6 Major Drugs, Now Available at Drugstore.com -- 'DrugConfirm' Is a New Revolutionary Urine Drug Test
2. Extreme Heat Causes Major Health Problems for Older Adults
3. Contract Talks for 1,800 Security Officers at Kaiser Permanente Break Down - Major Cuts to Worker Healthcare are at Issue
4. Nation Takes a Big Step Toward Learning Which Medical Treatments Work Best, a Major Advance in Fixing Our Broken Health-Care System
5. Major New Report Establishes Effective Methods of Enhancing and Preserving Brain Power as We Age
6. Major study highlights weight differences among 3-19 year-olds with type 1 and 2 diabetes
7. Beth Israel Medical Center Receives Major American Cancer Society Grant Toward Improving Pain Management in Chinese Cancer Patients
8. After Major Ruling on Unsafe Lead Levels in Paint, Experts Reveal How You Can Ensure Your Kids Are Safe
9. Former Senate Majority Leaders Baker, Daschle and Dole Release Bipartisan Framework for Comprehensive Health Reform
10. Prostate Cancer Patient Receives First RapidArc Radiotherapy Treatment at Major Danish Hospital
11. Report: Asbestos Litigation Disaster for Investors Could Be Repeated With Nanotechnology Unless SEC and FASB Close Eight Major Loopholes Now Preventing Honest Disclosures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... San Jose, CA (PRWEB) , ... April 25, ... ... in cross-screen access, support, and collaboration, announces Mirroring360 Pro . This new ... providing a comprehensive collaboration experience for education and business. , Mirroring360 Pro enables ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... CFOs and HR decision-makers are preparing for how his administration could impact the ... provide insight into what changes are most likely to make it through Congress. ...
(Date:4/25/2017)... Vegas, NV (PRWEB) , ... April 25, 2017 ... ... can now choose a modern procedure that achieves results in a fraction of ... in Las Vegas, NV, with Significance Dental Specialists, now offers this revolutionary ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving multi-billion ... head shops –can’t help but be heartened by the industry’s current surge. But another ... described as “skunk smell.” At last they can simply, safely and effectively end ...
(Date:4/25/2017)... ... 25, 2017 , ... There is no better place in South Florida to ... in the May issue of Consumer Reports focused on heart health. , The ... during and after coronary bypass and aortic valve replacement procedures. , Consumer Reports ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
Breaking Medicine Technology: